

Align. Measure. Perform. (AMP)  
Draft Measure Sets for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Commercial HMO	Commercial ACO	Medicare Advantage	Medi-Cal Managed Care
Clinical Quality	<b>Behavioral Health &amp; Substance Use</b>						
	1. Concurrent Use of Opioids and Benzodiazepines (COB)	PQA	Yes 3389	X	X	Info Only	X
	2. Use of Opioids at High Dosage (HDO)	NCQA	No	Info Only	Info Only	Info Only	Info Only
	3. Depression Screening and Follow-up for Adolescents and Adults (DSF-E)	NCQA	No	Testing			Testing
	<b>Cardiovascular</b>						
	4. Controlling High Blood Pressure (CBP)	NCQA	Yes 0018	X	X	X	X
	5. Proportion of Days Covered by Medications: Renin Angiotensin System Antagonists (PDCA)	PQA	Yes 0541	X		X	X
	6. Proportion of Days Covered by Medications: Statins (PDCS)	PQA	Yes 0541	X		X	X
	7. Statin Therapy for Patients With Cardiovascular Disease (SPC)	NCQA	No	X	X	X	X
	<b>Care Coordination</b>						
	8. Transitions of Care - Medication Reconciliation Post Discharge (TRC-MRP)	NCQA	Yes 0097				Testing
	<b>Diabetes</b>						
	9. Blood Pressure Control for Patients with Diabetes (BPD)	NCQA	No	X	X		X
	10. Eye Exam for Patients with Diabetes (EED)	NCQA	No	X	X	X	X
	11. Hemoglobin A1c Control for Patients With Diabetes: HbA1c control <8.0% (HBD)	NCQA	No	X			X
	12. Hemoglobin A1c Control for Patients With Diabetes: Poor HbA1c control >9.0% (HBD)	NCQA	No	X	X	X	X
	13. Kidney Evaluation in Patients with Diabetes (KED)	NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>
	14. Proportion of Days Covered by Medications: Diabetes All Class (PDCD)	PQA	Yes 0541	X		X	X
	15. Statin Therapy for Patients With Diabetes (SPD)	NCQA	No	X	X		X
	16. Statin Use in Persons with Diabetes (SUPD)	PQA	No 2712			X	
	<b>Maternity</b>						
	17. Prenatal and Postpartum Care (PPC)	NCQA	No 1517	Testing			X
	18. Prenatal Immunization Status (PRS-E)	NCQA	Yes 3484	First-Year <sup>A</sup>			First-Year <sup>A</sup>
	<b>Musculoskeletal</b>						
	19. Osteoporosis Management in Women Who Had a Fracture (OMW)	NCQA	Yes 0053			X	
	<b>Prevention and Screening</b>						
	20. Breast Cancer Screening (BCS-E)	NCQA	Yes 2372	X <sup>B</sup>	X <sup>B</sup>	X <sup>B</sup>	X <sup>B</sup>
21. Cervical Cancer Overscreening (CCO)	IHA-NCQA	No	X	X		X	
22. Cervical Cancer Screening (CCS)	NCQA	Yes 0032	X	X		X	
23. Child and Adolescent Well-Care Visits (WCV)	NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>		X	
24. Childhood Immunization Status: Combination 10 (CIS)	NCQA	Yes 0038	X	X		X	
25. Chlamydia Screening in Women (CHL)	NCQA	Yes 0033	X	X		X	
26. Colorectal Cancer Screening (COL)	NCQA	Yes 0034	X	X	X	X	
27. Immunizations for Adolescents: Combination 2 (IMA)	NCQA	Yes 1407	X	X		X	

<sup>A</sup> The adoption of these measures is dependent on evaluation of testing or baseline results from MY 2022.

<sup>B</sup> Breast Cancer Screening (BCS) will be updated for MY 2023 to become an Electronic Clinical Data Systems (ECDS) measure (BSC-E).

**Definitions:** X = Data collected for benchmarking and used for other programmatic purposes as applicable (e.g. public reporting, incentive design); Info Only = Data collected for benchmarking and not used for other programmatic purposes; Testing = Data collected to test measure validity prior to first-year inclusion, not used for other programmatic purposes; First-Year = Data collected to use for baseline prior to measure adoption, not used for other programmatic purposes.

Align. Measure. Perform. (AMP)  
Draft Measure Sets for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Commercial HMO	Commercial ACO	Medicare Advantage	Medi-Cal Managed Care
Clinical Quality	28. Well Child Visits in the First 30 Months of Life (W30)	NCQA	Yes 1392	Testing			Testing
	<del>Weight Assessment &amp; Counseling for Nutrition and Physical Activity for Children/Adolescents: BMI Percentile Documentation (WCC)</del>	<del>NCQA</del>	<del>Yes 0024</del>				<del>Retired</del>
	<b>Respiratory</b>						
	29. Appropriate Testing for Pharyngitis (CWP)	NCQA	No 0002	X	X		X
	30. Asthma Medication Ratio (AMR)	NCQA	Yes 1800	X	X		X
Data Quality	31. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	NCQA	Yes 0058	X	X		X
	32. Encounter Rate by Service Type (ENRST)	IHA-NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>
	33. Encounter Format (ENFMT)	IHA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>
	34. Encounter Timeliness (ENLAG)	IHA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>
Patient Experience	35. Access Composite	AHRQ	Yes 0005	X			X
	36. Care Coordination Composite	PBGH-AHRQ	No	X			X
	37. Office Staff Composite	AHRQ	Yes 0005	X			X
	38. Overall Ratings of Care Composite (Rating of Doctor & Rating of All Healthcare)	PBGH-AHRQ	No	X			X
	39. Provider Communication Composite	AHRQ	Yes 0005	X			X
Advancing Care Information	40. e-Measure: Controlling High Blood Pressure	NCQA	No	X			
	41. e-Measure: Screening for Depression & Follow Up Plan	CMS	No 0418e	X			
Appropriate Resource Use	42. Acute Hospital Utilization (AHU)	NCQA	No	X			
	43. All-Cause Readmissions (PCR)	NCQA	No 1768	X	X	Info Only	X
	44. Ambulatory Care: ED Visits (AMB)	NCQA	No				X
	45. Emergency Department Utilization (EDU)	NCQA	No	X	X		
	<del>Frequency of Selected Procedures (FSP)</del>	<del>NCQA</del>	<del>No</del>	<del>Retired</del>			<del>Retired</del>
	46. Generic Prescribing: Overall (GRX)	IHA	No	X			X
	47. Hospital Average Length of Stay: Maternity and Non-maternity (HALOS)	IHA-NCQA	No	Info Only	Info Only		Info Only
	48. Inpatient Utilization: General Hospital/Acute Care (IPU)	NCQA	No				X
	49. Outpatient Procedures Utilization - Percent Done in Preferred Facility (OSU)	IHA-NCQA	No	X			X
Cost	50. Total Cost of Care, incl service categories (TCOC)	HealthPartners	Yes 1604	X	X	Info Only	X

<sup>A</sup> The adoption of these measures is dependent on evaluation of testing or baseline results from MY 2022.

Definitions: X = Data collected for benchmarking and used for other programmatic purposes as applicable (e.g. public reporting, incentive design); Info Only = Data collected for benchmarking and not used for other programmatic purposes; Testing = Data collected to test measure validity prior to first-year inclusion, not used for other programmatic purposes; First-Year = Data collected to use for baseline prior to measure adoption, not used for other programmatic purposes.

AMP Commercial HMO  
Draft Measure Set for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Recommended For			Data Source
				Benchmarking	Payment	Public Reporting	
Clinical Quality	<b>Behavioral Health &amp; Substance Use</b>						
	1. Concurrent Use of Opioids and Benzodiazepines (COB)	PQA	Yes 3389	X	X	X	HP Claims Submission
	2. Use of Opioids at High Dosage (HDO)	NCQA	No	X			HP Claims Submission
	3. Depression Screening and Follow-up for Adolescents and Adults (DSF-E)	NCQA	No	Testing	Testing	Testing	HP and PO Clinical Submission
	<b>Cardiovascular</b>						
	4. Controlling High Blood Pressure (CBP)	NCQA	Yes 0018	X	X	X	HP and PO Clinical Submission
	5. Proportion of Days Covered by Medications: Renin Angiotensin System Antagonists (PDCA)	PQA	Yes 0541	X	X		HP and PO Clinical Submission
	6. Proportion of Days Covered by Medications: Statins (PCDS)	PQA	Yes 0541	X	X		HP and PO Clinical Submission
	7. Statin Therapy for Patients With Cardiovascular Disease (SPC)	NCQA	No	X	X	X	HP and PO Clinical Submission
	<b>Diabetes</b>						
	8. Blood Pressure Control for Patients with Diabetes (BPD)	NCQA	No	X	X	X	HP and PO Clinical Submission
	9. Eye Exam for Patients with Diabetes (EED)	NCQA	No	X	X	X	HP and PO Clinical Submission
	10. Hemoglobin A1c Control for Patients With Diabetes: HbA1c control <8.0% (HBD)	NCQA	No	X	X	X	HP and PO Clinical Submission
	11. Hemoglobin A1c Control for Patients With Diabetes: Poor HbA1c control >9.0% (HBD)	NCQA	No	X	X		HP and PO Clinical Submission
	12. Kidney Evaluation in Patients with Diabetes (KED)	NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	HP and PO Clinical Submission
	13. Proportion of Days Covered by Medications: Diabetes All Class (PDCD)	PQA	Yes 0541	X	X		HP and PO Clinical Submission
	14. Statin Therapy for Patients With Diabetes (SPD)	NCQA	No	X	X	X	HP and PO Clinical Submission
	<b>Maternity</b>						
	15. Prenatal and Postpartum Care (PPC)	NCQA	No 1517	Testing	Testing	Testing	HP and PO Clinical Submission
	16. Prenatal Immunization Status (PRS-E)	NCQA	Yes 3484	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	HP and PO Clinical Submission
	<b>Prevention and Screening</b>						
	17. Breast Cancer Screening (BCS-E)	NCQA	Yes 2372	X <sup>B</sup>	X <sup>B</sup>	X <sup>B</sup>	HP and PO Clinical Submission
	18. Cervical Cancer Overscreening (CCO)	IHA-NCQA	No	X	X	X	HP and PO Clinical Submission
	19. Cervical Cancer Screening (CCS)	NCQA	Yes 0032	X	X	X	HP and PO Clinical Submission
	20. Child and Adolescent Well-Care Visits (WCV)	NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	First-Year <sup>A</sup>	HP and PO Clinical Submission
21. Childhood Immunization Status: Combination 10 (CIS)	NCQA	Yes 0038	X	X	X	HP and PO Clinical Submission	
22. Chlamydia Screening in Women (CHL)	NCQA	Yes 0033	X	X	X	HP and PO Clinical Submission	
23. Colorectal Cancer Screening (COL)	NCQA	Yes 0034	X	X	X	HP and PO Clinical Submission	
24. Immunizations for Adolescents: Combination 2 (IMA)	NCQA	Yes 1407	X	X	X	HP and PO Clinical Submission	
25. Well Child Visits in the First 30 Months of Life (W30)	NCQA	Yes 1392	Testing	Testing	Testing	HP and PO Clinical Submission	

<sup>A</sup> The adoption of these measures is dependent on evaluation of testing or baseline results from MY 2022.

<sup>B</sup> Breast Cancer Screening (BCS) specifications will be updated for MY 2023 to become an Electronic Clinical Data Systems (ECDS) measure (BSC-E).

**Definitions:** X = Data collected and used for this programmatic purpose; Testing = Data collected to test measure validity prior to first-year inclusion, not used for this programmatic purpose; First-Year = Data collected to use for baseline prior to measure adoption, not used for this programmatic purpose.

AMP Commercial HMO  
Draft Measure Set for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Recommended For			Data Source
				Benchmarking	Payment	Public Reporting	
Clinical Quality	<b>Respiratory</b>						
	26. Appropriate Testing for Pharyngitis (CWP)	NCQA	No 0002	X	X	X	HP and PO Clinical Submission
	27. Asthma Medication Ratio (AMR)	NCQA	Yes 1800	X	X	X	HP and PO Clinical Submission
Data Quality	28. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	NCQA	Yes 0058	X	X	X	HP and PO Clinical Submission
	29. Encounter Rate by Service Type: Professional and Facility (ENRST)	IHA-NCQA	No	X	First-Year <sup>A</sup>		HP Clinical Submission
	30. Encounter Format (ENFMT)	IHA	No	X <sup>A</sup>	First-Year <sup>A</sup>		HP Claims Submission
Patient Experience	31. Encounter Timeliness (ENLAG)	IHA	No	X <sup>A</sup>	First-Year <sup>A</sup>		HP Claims Submission
	32. Access Composite	AHRQ	Yes 0005	X	X	X	PAS
	33. Care Coordination Composite	PBGH-AHRQ	No	X	X	X	PAS
Advancing Care Information	34. Office Staff Composite	AHRQ	Yes 0005	X	X	X	PAS
	35. Overall Ratings of Care Composite (Rating of Doctor & Rating of All Healthcare)	PBGH-AHRQ	No	X	X	X	PAS
	36. Provider Communication Composite	AHRQ	Yes 0005	X	X	X	PAS
Appropriate Resource Use	37. e-Measure: Controlling High Blood Pressure	NCQA	No	X	X		PO Clinical Submission
	38. e-Measure: Screening for Depression & Follow Up Plan	CMS	No 0418e	X	X		PO Clinical Submission
	39. Acute Hospital Utilization (AHU)	NCQA	No	X	X		HP Claims Submission
Appropriate Resource Use	40. All-Cause Readmissions (PCR)	NCQA	No 1768	X	X	X	HP Claims Submission
	41. Emergency Department Utilization (EDU)	NCQA	No	X	X		HP Claims Submission
	<del>Frequency of Selected Procedures (FSP)</del>	<del>NCQA</del>	<del>No</del>	<del>Retired</del>	<del>Retired</del>	<del>Retired</del>	<del>HP Claims Submission</del>
	42. Generic Prescribing: Overall (GRX)	IHA	No	X	X		HP Claims Submission
Appropriate Resource Use	43. Hospital Average Length of Stay: Maternity and Non-maternity (HALOS)	IHA-NCQA	No	X			HP Claims Submission
	44. Outpatient Procedures Utilization - Percent Done in Preferred Facility (OSU)	IHA-NCQA	No	X	X		HP Claims Submission
Cost	45. Total Cost of Care, incl service categories (TCOC)	HealthPartners	Yes 1604	X	X	X	HP Claims Submission

<sup>A</sup> The adoption of these measures is dependent on evaluation of testing or baseline results from MY 2022.

Definitions: X = Data collected and used for this programmatic purpose; Testing = Data collected to test measure validity prior to first-year inclusion, not used for this programmatic purpose; First-Year = Data collected to use for baseline prior to measure adoption, not used for this programmatic purpose.

AMP Commercial ACO  
Draft Measure Set for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Recommended For Benchmarking	Data Source
Clinical Quality	<b>Behavioral Health &amp; Substance Use</b>				
	1. Concurrent Use of Opioids and Benzodiazepines (COB)	PQA	Yes 3389	X	HP Claims Submission
	2. Use of Opioids at High Dosage (HDO)	NCQA	No	X <sup>B</sup>	HP Claims Submission
	<b>Cardiovascular</b>				
	3. Controlling High Blood Pressure (CBP)	NCQA	Yes 0018	X	HP Claims Submission
	4. Statin Therapy for Patients With Cardiovascular Disease (SPC)	NCQA	No	X	HP Claims Submission
	<b>Diabetes</b>				
	5. Blood Pressure Control for Patients with Diabetes (BPD)	NCQA	No	X	HP Claims Submission
	6. Eye Exam for Patients with Diabetes (EED)	NCQA	No	X	HP Claims Submission
	7. Hemoglobin A1c Control for Patients With Diabetes: Poor HbA1c control >9.0% (HBD)	NCQA	No	X	HP Claims Submission
	9. Kidney Evaluation in Patients with Diabetes (KED)	NCQA	No	First-Year <sup>A</sup>	HP Claims Submission
	10. Statin Therapy for Patients With Diabetes (SPD)	NCQA	No	X	HP Claims Submission
	<b>Prevention and Screening</b>				
	11. Breast Cancer Screening (BCS-E)	NCQA	Yes 2372	X <sup>C</sup>	HP Claims Submission
	12. Cervical Cancer Overscreening (CCO)	IHA-NCQA	No	X	HP Claims Submission
	13. Cervical Cancer Screening (CCS)	NCQA	Yes 0032	X	HP Claims Submission
	14. Child and Adolescent Well-Care Visits (WCV)	NCQA	No	First-Year <sup>A</sup>	HP Claims Submission
	15. Childhood Immunization Status: Combination 10 (CIS)	NCQA	Yes 0038	X	HP Claims Submission
	16. Chlamydia Screening in Women (CHL)	NCQA	Yes 0033	X	HP Claims Submission
	17. Colorectal Cancer Screening (COL)	NCQA	Yes 0034	X	HP Claims Submission
	18. Immunizations for Adolescents: Combination 2 (IMA)	NCQA	Yes 1407	X	HP Claims Submission
	<b>Respiratory</b>				
19. Appropriate Testing for Pharyngitis (CWP)	NCQA	No 0002	X	HP Claims Submission	
20. Asthma Medication Ratio (AMR)	NCQA	Yes 1800	X	HP Claims Submission	
21. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	NCQA	Yes 0058	X	HP Claims Submission	
22. Encounter Rate by Service Type (ENRST)	IHA-NCQA	No	First-Year	HP Clinical Submission	
23. Encounter Format (ENFMT)	IHA	No	First-Year	HP Claims Submission	
24. Encounter Timeliness (ENLAG)	IHA	No	First-Year	HP Claims Submission	
Appropriate Resource Use	25. All-Cause Readmissions (PCR)	NCQA	No 1768	X	HP Claims Submission
	26. Emergency Department Utilization (EDU)	NCQA	No	X	HP Claims Submission
	27. Hospital Average Length of Stay: Maternity and Non-maternity (HALOS)	IHA-NCQA	No	X	HP Claims Submission
Cost	28. Total Cost of Care, incl service categories (TCOC)	HealthPartners	Yes 1604	X	HP Claims Submission

<sup>A</sup>The adoption of these measures is dependent on evaluation of testing or baseline results from MY 2022.

<sup>B</sup>These measures are excluded from the calculation of the overall composite performance score (e.g. Quality Index Score).

<sup>C</sup>Breast Cancer Screening (BCS) specifications will be updated for MY 2023 to become an Electronic Clinical Data Systems (ECDS) measure (BSC-E).

**Definitions:** X = Data collected and used for benchmarking; Testing = Data collected to test measure validity prior to first-year inclusion, not used for benchmarking; First-Year = Data collected to use for baseline prior to measure adoption, not used for benchmarking.

# AMP Medicare Advantage Draft Measure Set for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Recommended For		Data Source
				Benchmarking	Public Reporting	
Clinical Quality	<b>Behavioral Health &amp; Substance Use</b>					
	1. Concurrent Use of Opioids and Benzodiazepines (COB)	PQA	Yes 3389	X		HP Claims Submission
	2. Use of Opioids at High Dosage (HDO)	NCQA	No	X		HP Claims Submission
	<b>Cardiovascular</b>					
	3. Controlling High Blood Pressure (CBP)	NCQA	Yes 0018	X	X	HP and PO Clinical Submission
	4. Proportion of Days Covered by Medications: Renin Angiotensin System Antagonists (PDCA)	PQA	Yes 0541	X	X	HP and PO Clinical Submission
	5. Proportion of Days Covered by Medications: Statins (PDCS)	PQA	Yes 0541	X	X	HP and PO Clinical Submission
	6. Statin Therapy for Patients With Cardiovascular Disease (SPC)	NCQA	No	X	X	HP and PO Clinical Submission
	<b>Care Coordination</b>					
	7. Transitions of Care - Medication Reconciliation Post Discharge (TRC)	NCQA	Yes 0097	Testing	Testing	HP and PO Clinical Submission
	<b>Diabetes</b>					
	8. Eye Exam for Patients with Diabetes (EED)	NCQA	No	X	X	HP and PO Clinical Submission
	9. Hemoglobin A1c Control for Patients With Diabetes: Poor HbA1c control >9.0% (HBD)	NCQA	No	X	X	HP and PO Clinical Submission
	10. Proportion of Days Covered by Medications: Diabetes All Class (PDCD)	PQA	Yes 0541	X	X	HP and PO Clinical Submission
	11. Kidney Evaluation in Patients with Diabetes (KED)	NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	HP and PO Clinical Submission
	12. Statin Use in Persons with Diabetes (SUPD)	PQA	No 2712	X	X	HP Claims/PO Clinical Submission
	<b>Musculoskeletal</b>					
	13. Osteoporosis Management in Women Who Had a Fracture (OMW)	NCQA	Yes 0053	X	X	HP and PO Clinical Submission
<b>Prevention and Screening</b>						
14. Breast Cancer Screening (BCS-E)	NCQA	Yes 2372	X <sup>B</sup>	X <sup>B</sup>	HP and PO Clinical Submission	
15. Colorectal Cancer Screening (COL)	NCQA	Yes 0034	X	X	HP and PO Clinical Submission	
Data Quality	16. Encounter Rate by Service Type: Professional and Facility (ENRST)	IHA-NCQA	No	X	First-Year <sup>A</sup>	HP Clinical Submission
	17. Encounter Format (ENFMT)	IHA	No	X <sup>A</sup>	First-Year <sup>A</sup>	HP Claims Submission
	18. Encounter Timeliness (ENLAG)	IHA	No	X <sup>A</sup>	First-Year <sup>A</sup>	HP Claims Submission
Appropriate Resource Use	19. All-Cause Readmissions (PCR)	NCQA	No 1768	X		HP Claims Submission
Cost	20. Total Cost of Care, incl service categories (TCOC)	HealthPartners	Yes 1604	X		HP Claims Submission

<sup>A</sup> The adoption of these measures is dependent on evaluation of testing results from MY 2022.

<sup>B</sup> Breast Cancer Screening (BCS) specifications will be updated for MY 2023 to become an Electronic Clinical Data Systems (ECDS) measure (BSC-E).

**Definitions:** X = Data collected and used for this programmatic purpose; Testing = Data collected to test measure validity prior to first-year inclusion, not used for this programmatic purpose; First-Year = Data collected to use for baseline prior to measure adoption, not used for this programmatic purpose.

AMP Medi-Cal Managed Care  
Draft Measure Set for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Recommended For		Data Source
				Benchmarking	Payment	
Clinical Quality	<b>Behavioral Health &amp; Substance Use</b>					
	1. Concurrent Use of Opioids and Benzodiazepines (COB)	PQA	Yes 3389	X	X	HP Claims Submission
	2. Use of Opioids at High Dosage (HDO)	NCQA	No	X		HP Claims Submission
	3. Depression Screening and Follow-up for Adolescents and Adults (DSF-E)	NCQA	No	Testing	Testing	HP Claims / PO Clinical Submission <sup>B</sup>
	<b>Cardiovascular</b>					
	4. Controlling High Blood Pressure (CBP)	NCQA	Yes 0018	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	5. Proportion of Days Covered by Medications: Renin Angiotensin System Antagonists (PDCA)	PQA	Yes 0541	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	6. Proportion of Days Covered by Medications: Statins (PDCS)	PQA	Yes 0541	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	7. Statin Therapy for Patients With Cardiovascular Disease (SPC)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	<b>Diabetes</b>					
	8. Blood Pressure Control for Patients with Diabetes (BPD)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	9. Eye Exam for Patients with Diabetes (EED)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	10. Hemoglobin A1c Control for Patients With Diabetes: HbA1c control <8.0% (HBD)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	11. Hemoglobin A1c Control for Patients With Diabetes: Poor HbA1c control >9.0% (HBD)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	12. Kidney Evaluation for Patients with Diabetes	NCQA	No	First-Year <sup>A</sup>	First-Year <sup>A</sup>	HP Claims / PO Clinical Submission <sup>B</sup>
	13. Proportion of Days Covered by Medications: Diabetes All Class (PDCD)	PQA	Yes 0541	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	14. Statin Therapy for Patients With Diabetes (SPD)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	<b>Maternity</b>					
	15. Prenatal and Postpartum Care (PPC)	NCQA	No 1517	X		HP Claims / PO Clinical Submission <sup>B</sup>
	16. Prenatal Immunization Status (PRS-E)	NCQA	Yes 3484	First-Year <sup>A</sup>	First-Year <sup>A</sup>	HP Claims / PO Clinical Submission <sup>B</sup>
	<b>Prevention and Screening</b>					
	17. Breast Cancer Screening (BCS-E)	NCQA	Yes 2372	X <sup>C</sup>	X <sup>C</sup>	HP Claims / PO Clinical Submission <sup>B</sup>
	18. Cervical Cancer Overscreening (CCO)	IHA-NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	19. Cervical Cancer Screening (CCS)	NCQA	Yes 0032	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
20. Child and Adolescent Well-Care Visits (WCV)	NCQA	No	X	X	HP Claims / PO Clinical Submission <sup>B</sup>	
21. Childhood Immunization Status: Combination 10 (CIS)	NCQA	Yes 0038	X	X	HP Claims / PO Clinical Submission <sup>B</sup>	
22. Chlamydia Screening in Women (CHL)	NCQA	Yes 0033	X	X	HP Claims / PO Clinical Submission <sup>B</sup>	
23. Colorectal Cancer Screening (COL)	NCQA	Yes 0034	X	X	HP Claims / PO Clinical Submission <sup>B</sup>	
24. Immunizations for Adolescents: Combination 2 (IMA)	NCQA	Yes 1407	X	X	HP Claims / PO Clinical Submission <sup>B</sup>	

<sup>A</sup> The adoption of these measures is dependent on evaluation of baseline results from MY 2022.

<sup>B</sup> Measure data source may change to HP and PO Clinical Submission beginning in MY 2022.

<sup>C</sup> Breast Cancer Screening (BCS) specifications will be updated for MY 2023 to become an Electronic Clinical Data Systems (ECDS) measure (BSC-E).

Definitions: X = Data collected and used for this programmatic purpose; Testing = Data collected to test measure validity prior to first-year inclusion, not used for this programmatic purpose; First-Year = Data collected to use for baseline prior to measure adoption, not used for this programmatic purpose.

AMP Medi-Cal Managed Care  
Draft Measure Set for Measurement Year 2023

RED - MY 2023 changes compared to MY 2022 measure set



Measure Domain	Measure Name	Measure Steward	NQF Endorsed	Recommended For		Data Source
				Benchmarking	Payment	
Clinical Quality	25. Well Child Visits in the First 30 Months of Life (W30)	NCQA	Yes 1392	Testing	Testing	HP Claims / PO Clinical Submission <sup>B</sup>
	<del>Weight Assessment &amp; Counseling for Nutrition and Physical Activity for Children/Adolescents: BMI Percentile Documentation (WCC)</del>	<del>NCQA</del>	<del>Yes 0024</del>	<del>Retired</del>	<del>Retired</del>	<del>HP Claims / PO Clinical Submission<sup>B</sup></del>
	<b>Respiratory</b>					
	26. Appropriate Testing for Pharyngitis (CWP)	NCQA	No 0002	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	27. Asthma Medication Ratio (AMR)	NCQA	Yes 1800	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
Data Quality	28. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	NCQA	Yes 0058	X	X	HP Claims / PO Clinical Submission <sup>B</sup>
	29. Encounter Rate by Service Type: Professional and Facility (ENRST)	IHA-NCQA	No	X	First-Year <sup>A</sup>	HP Clinical Submission
	30. Encounter Format (ENFMT)	IHA	No	X <sup>A</sup>	First-Year <sup>A</sup>	HP Claims Submission
	31. Encounter Timeliness (ENLAG)	IHA	No	X <sup>A</sup>	First-Year <sup>A</sup>	HP Claims Submission
Patient Experience	32. Access Composite	AHRQ	Yes 0005	X	X	PAS
	33. Care Coordination Composite	PBGH-AHRQ	No	X	X	PAS
	34. Office Staff Composite	AHRQ	Yes 0005	X	X	PAS
	35. Overall Ratings of Care Composite (Rating of Doctor & Rating of All Healthcare)	PBGH-AHRQ	No	X	X	PAS
	36. Provider Communication Composite	AHRQ	Yes 0005	X	X	PAS
Appropriate Resource Use	37. All-Cause Readmissions (PCR)	NCQA	No 1768	X	X	HP Claims Submission
	38. Ambulatory Care: ED Visits (AMB)	NCQA	No	X	X	HP Claims Submission
	<del>Frequency of Selected Procedures (FSP)</del>	<del>NCQA</del>	<del>No</del>	<del>Retired</del>	<del>Retired</del>	<del>HP Claims Submission</del>
	39. Generic Prescribing: Overall (GRX)	IHA	No	X	X	HP Claims Submission
	40. Hospital Average Length of Stay: Maternity and Non-maternity (HALOS)	IHA-NCQA	No	X		HP Claims Submission
	41. Inpatient Utilization: General Hospital/Acute Care (IPU)	NCQA	No	X	X	HP Claims Submission
Cost	42. Outpatient Procedures Utilization - Percent Done in Preferred Facility (OSU)	IHA-NCQA	No	X	X	HP Claims Submission
	43. Total Cost of Care, incl service categories (TCOC)	HealthPartners	Yes 1604	X	X	HP Claims Submission

<sup>A</sup> The adoption of these measures is dependent on evaluation of testing or baseline results from MY 2022.

<sup>B</sup> Measure data source may change to HP and PO Clinical Submission beginning in MY 2022.

Definitions: X = Data collected and used for this programmatic purpose; Testing = Data collected to test measure validity prior to first-year inclusion, not used for this programmatic purpose; First-Year = Data collected to use for baseline prior to measure adoption, not used for this programmatic purpose.